• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page


Karyopharm - oncology

Quote
anonymous said:
Gee, does this mean that Ricky’s brilliance won’t deliver the goods?


Analyst Forecasts Just Became More Bearish On Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Simply Wall St News

https://simplywall.st/stocks/us/pha...ts-just-became-more-bearish-on-karyopharm-the

Market forces rained on the parade of Karyopharm Therapeutics Inc.(NASDAQ:KPTI) shareholders today, when the analysts downgraded their forecasts for this year. Revenue estimates were cut sharply as analysts signalled a weaker outlook - perhaps a sign that investors should temper their expectations as well.

Following the downgrade, the consensus from nine analysts covering Karyopharm Therapeutics is for revenues of US$99m in 2021, implying a perceptible 3.7% decline in sales compared to the last 12 months. Losses are forecast to hold steady at around US$2.80. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$119m and losses of US$2.82 per share in 2021. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a serious cut to their revenue forecasts while also making no real change to the loss per share numbers.
Click to expand...

The inverse of the Midas touch? The RP touch. Judging from analysts line of questioning, they are not impressed.
 








Lower revenue in Q2 21 vs Q1 21. That’s all you need to know. We hit peak share/revenue in Q1. Until a new indication this is what revenue will look like within a few million either way. Fingers crossed we have positive data for future indications. If our BOD had any sense they’d put the for sale up for $20 a share and call it a day.
 












anonymous said:
Lower revenue in Q2 21 vs Q1 21. That’s all you need to know. We hit peak share/revenue in Q1. Until a new indication this is what revenue will look like within a few million either way. Fingers crossed we have positive data for future indications. If our BOD had any sense they’d put the for sale up for $20 a share and call it a day.
Click to expand...
You clearly dont understand the market. Good companies that have growing revenue get a 30-50 percent premium. This place is a steaming turd.
 




anonymous said:
You clearly dont understand the market. Good companies that have growing revenue get a 30-50 percent premium. This place is a steaming turd.
Click to expand...

Ha! Good point...I was a bit optimistic with the $20 number. Thanks for keeping us honest!

Calling this place a steaming turd would be an insult to steaming turds...but that would be too easy.
 








































anonymous said:
The only reps remaining have questionable insight and judgement (and numbers) or you would have left already.
Click to expand...

Unfortunately there hasn’t been anything all that exciting to leave for…Legend, ADC, Oncopeptides, CTI? That’s just jumping from bad to maybe not as bad. I think many of us are merely biding our time to land in a better spot.
 
















Top Bottom
Back
Quote